The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Congressionally Directed Medical Research Programs -- Peer Reviewed Alzheimer’s Disease Research Program -- New Investigator Research Award
The PRARP New Investigator Research Award (NIRA) mechanism is being offered for the first time in FY17.
The intent of the FY17 PRARP NIRA is to support early-career investigators interested in novel research efforts or new technologies within TBI and AD/ADRD in support of the PRARP’s mission (see Section II.A, Program Description).
The FY17 PRARP NIRA is open to Principal Investigators (PIs) within 3 years of their first independent faculty position, from any field or discipline. As part of the application, the PI should demonstrate that the study team has experience in both TBI and AD/ADRD research. Preliminary data, while not required, are encouraged. Preliminary data may come from the PI’s published work, pilot data, or from peer-reviewed literature. Note that PIs will be required to verify their eligibility for this award
- REQUIRED Pre-application Submission Deadline: September 21, 2017 (was September 6, 2017)
- Full Application Submission Deadline: October 5, 2017 (was September 20, 2017)
Areas of Interest
FY17 PRARP NIRA Overarching Challenges: This FY17 PRARP NIRA funding opportunity requires applications to address one or more of the following FY17 PRARP NIRA Overarching Challenges:
• Paucity of Research Resources: The paucity of research resources to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities.
• Paucity of Clinical Studies: The paucity of clinical studies to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities. This includes research into risk factors which may predispose individuals to AD/ADRD subsequent to TBI.
• Diagnostic Technologies, Tests, Biomarkers, or Devices: The need for technologies, tests, or devices to detect or prognose the progression to AD/ADRD subsequent to TBI. This includes research into risk factors that may predispose individuals to AD/ADRD subsequent to TBI.
• Quality of Life: The need for technologies, assessments, interventions, or devices to benefit individuals living with the common symptoms or deficits of TBI and AD/ADRD.
• Caregiver Burden: The need for technologies, assessments, interventions, or devices with the goal of reducing burden for caregivers of individuals living with the common symptoms or deficits of TBI and AD/ADRD.
• Epidemiology: The paucity of epidemiological research to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities. This includes research into risk factors that may predispose individuals to AD/ADRD subsequent to TBI.
FY17 PRARP NIRA Focus Areas: In addition to addressing one or more of the specified FY17 PRARP NIRA Overarching Challenges, applications should address at least one of the following FY17 PRARP NIRA Focus Areas in support of the FY17 PRARP NIRA Overarching Challenges. An application that proposes research outside of the FY17 PRARP NIRA Focus Areas is acceptable, as long as the applicant provides a strong rationale.
• Genomics/Proteomics: Studies or technologies (e.g., genetic, proteomic, bioinformatics, and epigenetic strategies) intended to characterize neurological change(s) associated with TBI and subsequent AD/ADRD. In addition, relevant technologies or tests may be considered under this Focus Area.
• Mechanisms of Pathogenesis: Identification of contributing mechanisms (e.g., pathology of Tau, non-neuronal cells, inflammatory factors, and vascular contributions) associated with TBI and subsequent AD/ADRD pathogenesis.
• Quality of Life: Research intended to alleviate, stabilize, or characterize the symptoms or deficits common to TBI and AD/ADRD. Examples of research in this Focus Area include identification and management of comorbidities and modifiable risk factors (e.g., sleep apnea, obesity), cognitive training interventions, studies of health and wellness, and behavioral interventions.
• Caregiver Support: Research intended to reduce the burden of care on the caregiver for individuals living with the common symptoms or deficits of TBI and AD/ADRD. Examples of research in this focus area include: caregiver training, home-based support, behavioral interventions, and relationship interventions.
• Biomarkers: Development of strategies to diagnose, prognose, or characterize neurological changes or risk factors associated with TBI and subsequent AD/ADRD (e.g., fluid-based, imaging, physiological, and clinical approaches).
• Novel Target Identification: Basic research (non-human) directly leading to the identification of new targets for the development of existing or new investigational medicines, drugs, or agents.
• Epidemiological Research: Research focusing on the incidence, distribution, and other factors relating to the health of individuals affected by TBI and subsequent AD/ADRD.
The PI must be an independent, early-career investigator within 3 years of his/her first independent faculty position (or equivalent).
The anticipated direct costs budgeted for the entire period of performance for an FY17 PRARP NIRA will not exceed $225,000. The maximum period of performance is 3 years. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.